Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2007

01.03.2007 | Clinical-Patient Studies

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

verfasst von: Marc C. Chamberlain, Michael J. Glantz, Lisa Chalmers, Alixis Van Horn, Andrew E. Sloan

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.
Literatur
1.
Zurück zum Zitat Stupp R, Dietrich P-Y, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRef Stupp R, Dietrich P-Y, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRef
2.
Zurück zum Zitat Stupp R, Mason WP, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996CrossRef Stupp R, Mason WP, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996CrossRef
3.
Zurück zum Zitat Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266PubMedCrossRef Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266PubMedCrossRef
4.
Zurück zum Zitat Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRef Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRef
6.
Zurück zum Zitat Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual data from 12 randomized trials. Lancet 359:1011–1018PubMedCrossRef Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual data from 12 randomized trials. Lancet 359:1011–1018PubMedCrossRef
7.
Zurück zum Zitat de Wit MCY, de Bruin HG, Eijkenboom W, Sillevis-Smitt PAE, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535–537PubMed de Wit MCY, de Bruin HG, Eijkenboom W, Sillevis-Smitt PAE, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63:535–537PubMed
8.
Zurück zum Zitat Cross NE, Glantz MJ (2003) Neurologic complications of radiation therapy. In Wen PY, Glantz MJ (eds) Complications of Systemic Cancer. W.B. Saunders Co., Philadelphia, pp 249–277 Cross NE, Glantz MJ (2003) Neurologic complications of radiation therapy. In Wen PY, Glantz MJ (eds) Complications of Systemic Cancer. W.B. Saunders Co., Philadelphia, pp 249–277
Metadaten
Titel
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
verfasst von
Marc C. Chamberlain
Michael J. Glantz
Lisa Chalmers
Alixis Van Horn
Andrew E. Sloan
Publikationsdatum
01.03.2007
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2007
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-006-9241-y

Weitere Artikel der Ausgabe 1/2007

Journal of Neuro-Oncology 1/2007 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.